Silo pharma to participate in fda meeting exploring emerging therapeutic interest in ketamine

Silo's sp-26 currently in development utilizes ketamine as primary therapeutic agent silo's sp-26 currently in development utilizes ketamine as primary therapeutic agent

SILO Ratings Summary

SILO Quant Ranking